SCYNEXIS (SCYX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 25, 2025, at 9:30 AM EDT, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials and vote by June 24, 2025, 11:59 PM ET.
Voting matters and shareholder proposals
Election of seven directors is on the agenda, with nominees listed for shareholder approval.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2025.
Advisory vote on executive compensation for named executive officers.
Provision to conduct any other business properly brought before the meeting.
Board of directors and corporate governance
Seven director nominees are presented for election: David Angulo, Armando Anido, Steven C. Gilman, Ann F. Hanham, David Hastings, Guy Macdonald, and Philippe Tinmouth.
Latest events from SCYNEXIS
- SCY-247 advances as a potent antifungal with strong clinical data and significant market potential.SCYX
investor presentation4 Mar 2026 - 2025 revenue rose sharply on GSK deals; SCY-247 clinical progress and cash runway extended.SCYX
Q4 20254 Mar 2026 - Advancing next-gen antifungal SCY-247 and expanding GSK partnership, with strong financials.SCYX
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Shareholders will vote on directors, auditor ratification, and executive pay, all board-recommended.SCYX
Proxy Filing2 Dec 2025 - Secured $24.8M from GSK, advanced SCY-247, and extended cash runway beyond two years.SCYX
Q3 20256 Nov 2025 - Q2 net loss narrowed, cash runway extended, but GSK dispute and Nasdaq risk persist.SCYX
Q2 202514 Aug 2025 - Q3 2024 saw a net loss, no product sales, and ongoing clinical hold, with $84.9M in liquidity.SCYX
Q3 202413 Jun 2025 - Q2 net loss of $14.5M, no product sales, $10M milestone expected, cash at $83.7M.SCYX
Q2 202413 Jun 2025 - Q1 2025 saw a $5.4M net loss, GSK dispute, and China approval for ibrexafungerp.SCYX
Q1 20256 Jun 2025